Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Vasc Access ; 7(3): 112-7, 2006.
Article in English | MEDLINE | ID: mdl-17019662

ABSTRACT

PURPOSE: Treprostinil is approved for the treatment of pulmonary arterial hypertension (PAH) via continuous intravenous (IV) infusion. Treprostinil's anti-platelet aggregation characteristics and stability at room temperature may allow for low infusion rates (0.1-0.2 mL/hr) using a miniaturized infusion pump. METHODS: A 12-week, multi-center, open-label study in 12 adult PAH patients, evaluated the feasibility and safety of low-flow IV treprostinil administration via the 407C miniaturized pump. Patients receiving IV treprostinil at a stable dose were transitioned from their current CADD-Legacy pump to the 407C and were assessed for adverse events including catheter occlusions, pump alarms, and efficacy (six minute walk distance (6MWD), Borg Dyspnea Score (BDS), NYHA functional class, and PAH signs/symptoms). All patients were also maintained on therapeutic doses of warfarin, heparin or low molecular weight heparin throughout the study. RESULTS: Baseline mean (+/-SD) 6MWD was 477 +/- 76 m (n = 9) with mean BDS of 2.1 +/- 1.2 (n = 9). Week 12 mean 6MWD and BDS were 500 +/- 92 m and 2.3 +/- 1.7, respectively (n = 9). Four patients discontinued the study prematurely (3 AEs and 1 consent withdrawn). Adverse events included headache, flushing, and nausea. Pump complications occurred in 5 of 12 patients, and although no catheter occlusions occurred in any patient during the 12-week study, further study is needed regarding pump complications. CONCLUSION: This study demonstrates that treprostinil can be administered intravenously at infusion rates as low as 0.1 mL/hr for 12 weeks without catheter occlusions. Further studies are warranted because the potential for adverse events is of some concern.


Subject(s)
Antihypertensive Agents/administration & dosage , Epoprostenol/analogs & derivatives , Hypertension, Pulmonary/drug therapy , Infusion Pumps , Adult , Antihypertensive Agents/adverse effects , Dyspnea/physiopathology , Epoprostenol/administration & dosage , Epoprostenol/adverse effects , Equipment Design , Exercise Tolerance/drug effects , Feasibility Studies , Female , Humans , Hypertension, Pulmonary/physiopathology , Infusion Pumps/adverse effects , Infusions, Intravenous , Male , Middle Aged , Severity of Illness Index , Time Factors , Treatment Outcome , United States/epidemiology , Walking
2.
Eur Respir J ; 24(3): 371-4, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15358693

ABSTRACT

The aim of the present study was to determine if patients with both pulmonary arterial hypertension (PAH), due to pulmonary vascular obstructive disease, and congenital heart defects (CHD), have mutations in the gene encoding bone morphogenetic protein receptor (BMPR)-2. The BMPR2 gene was screened in two cohorts: 40 adults and 66 children with PAH/CHD. CHDs were patent ductus arteriosus, atrial and ventricular septal defects, partial anomalous pulmonary venous return, transposition of the great arteries, atrioventicular canal, and rare lesions with systemic-to-pulmonary shunts. Six novel missense BMPR2 mutations were found in three out of four adults with complete type C atrioventricular canals and in three children. One child had an atrial septal defect and patent ductus arteriosus; one had an atrial septal defect, patent ductus arteriosus and partial anomalous pulmonary venous return; and one had an aortopulmonary window and a ventricular septal defect. Bone morphogenetic protein receptor 2 mutations were found in 6% of a mixed cohort of adults and children with pulmonary arterial hypertension/congenital heart defects. The current findings compliment recent reports in mouse models implicating members of the bone morphogenetic protein/transforming growth factor-beta pathway inducing cardiac anomalies analogous to human atrioventricular canals, septal defects and conotruncal congenital heart defects. The small number of patients studied and the ascertainment bias inherent in selecting for pulmonary arterial hypertension require further investigation.


Subject(s)
Heart Defects, Congenital/complications , Heart Defects, Congenital/genetics , Hypertension, Pulmonary/complications , Hypertension, Pulmonary/genetics , Mutation, Missense/genetics , Protein Serine-Threonine Kinases/genetics , Adult , Bone Morphogenetic Protein Receptors, Type II , Child , Cohort Studies , Humans , Receptors, Cell Surface/genetics , Sequence Analysis, DNA
3.
Eur Respir J ; 21(1): 155-76, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12570125

ABSTRACT

For physicians to admit that a group of patients remains for whom no cure is available in modern medicine is intellectually unsatisfying. Pulmonary arterial hypertension is a rare condition. Because the symptoms are nonspecific and the physical finding can be subtle, the disease is often diagnosed in its later stages. The natural history of pulmonary arterial hypertension is usually progressive and fatal. At the 1998 Primary Pulmonary Hypertension World Symposium, clinical scientists from around the world gathered to review and discuss the future of pulmonary arterial hypertension. Bringing together experts from a variety of disciplines provided the opportunity for a better understanding of the pathology, pathobiology, risk factors, genetics, diagnosis and treatment for pulmonary arterial hypertension. Remarkable progress has been made in the field of pulmonary arterial hypertension over the past several decades. The pathology is now better defined and significant advances have occurred in understanding the pathobiological mechanisms. Risk factors have been identified and the genetics have been characterised. Advances in technology allow earlier diagnosis as well as better assessment of disease severity. Therapeutic modalities such as new drugs, e.g. epoprostenol, treprostinil and bosentan, and surgical interventions, e.g. transplantation and blade septostomy, which were unavailable several decades ago, have had a significant impact on prognosis and outcome. Thus, despite the inability to really cure pulmonary arterial hypertension, therapeutic advances over the past two decades have resulted in significant improvements in the outcome for children with various forms of pulmonary arterial hypertension. This review of pulmonary arterial hypertension will highlight the key features of pulmonary hypertension in infants and children and the current understanding of pulmonary arterial hypertension with specific recommendations for current practice and future directions.


Subject(s)
Hypertension, Pulmonary , Cardiac Catheterization , Child , Endothelin Receptor Antagonists , Enzyme Inhibitors/therapeutic use , Epoprostenol/therapeutic use , Genetic Therapy , Heart Septum/surgery , Heart Transplantation , Heart-Lung Transplantation , Humans , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/epidemiology , Hypertension, Pulmonary/physiopathology , Hypertension, Pulmonary/therapy , Infant , Lung Transplantation , Nitric Oxide/therapeutic use , Oxygen Inhalation Therapy , Physical Examination , Prognosis , Receptor, Endothelin A , Risk Factors , Vasodilator Agents
SELECTION OF CITATIONS
SEARCH DETAIL
...